References of "Kolh, Philippe"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailNew biomarkers for primary mitral regurgitation.
Deroyer, Céline ULg; Magne, Julien; Moonen, Marie ULg et al

in Clinical proteomics (2015), 12

BACKGROUND: Mitral regurgitation is a frequent valvular heart disease affecting around 2.5 % of the population with prevalence directly related to aging. Degeneration of mitral valve is broadly considered ... [more ▼]

BACKGROUND: Mitral regurgitation is a frequent valvular heart disease affecting around 2.5 % of the population with prevalence directly related to aging. Degeneration of mitral valve is broadly considered as a passive ongoing pathophysiological process and little is known about its physiological deregulation. The purpose of this study was to highlight new biomarkers of mitral regurgitation in order to decipher the underlying pathological mechanism as well as to allow the diagnosis and the monitoring of the disease. RESULTS: Modulation of various blood proteins expression was examined in patients suffering from different grades of mitral regurgitation (mild, moderate and severe) compared to healthy controls. To this end, several routine clinical assays and the multi analyte profile technology targeting 184 proteins were used. High-density lipoprotein, apolipoprotein-A1, haptoglobin and haptoglobin-alpha2 chain levels significantly decreased proportionally to the degree of mitral regurgitation when compared to controls. High-density lipoprotein and apolipoprotein-A1 levels were associated with effective regurgitant orifice area and regurgitant volume. Apolipoprotein-A1 was an independent predictor of severe mitral regurgitation. Moreover, with ordinal logistic regression, apolipoprotein-A1 remained the only independent factor associated with mitral regurgitation. In addition, myxomatous mitral valves were studied by immunocytochemistry. We observed an increase of LC3, the marker of autophagy, in myxomatous mitral valves compared with healthy mitral valves. CONCLUSION: These potential biomarkers of mitral regurgitation highlighted different cellular processes that could be modified in myxomatous degenerescence: reverse cholesterol transport, antioxidant properties and autophagy. [less ▲]

Detailed reference viewed: 79 (16 ULg)
Full Text
Peer Reviewed
See detailImpact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis.
Siller-Matula, Jolanta M.; Petre, Alexandra; Delle-Karth, Georg et al

in European heart journal. Acute cardiovascular care (2015)

OBJECTIVE: To review systematically the evidence and perform a meta-analysis of benefits and risks associated with use of P2Y12 receptor inhibitors in coronary artery bypass graft-, non-cardiac- and ... [more ▼]

OBJECTIVE: To review systematically the evidence and perform a meta-analysis of benefits and risks associated with use of P2Y12 receptor inhibitors in coronary artery bypass graft-, non-cardiac- and device surgery. DATA SELECTION AND ANALYSIS: We performed a meta-analysis of published studies. Patients with preoperative use of clopidogrel, ticagrelor or prasugrel (late discontinuation: <5 days before surgery or no discontinuation) were compared with patients without preoperative use of the respective drug (early discontinuation: 5 days before surgery or no users of P2Y12 receptor inhibitors). Outcomes evaluated were re-operation for major bleeding, death, myocardial infarction, combined major adverse cardiac events (MACEs) and major haematoma. Using a random effect model, relative risks (RRs) and 95% confidence intervals (CI) were calculated for each outcome. RESULTS: Fifty-four studies met the selection criteria and included 50,048 patients. Preoperative use of clopidogrel on top of aspirin in patients undergoing coronary artery bypass graft was associated with a 2.5-fold increased risk of re-operation for bleeding (95% CI: 1.92-3.25; p<0.001) and a 1.47-fold increased risk of death (95% CI: 1.25-1.72; p<0.001), but did not diminish the risk for myocardial infarction (RR: 0.96; 95% CI: 0.75-1.25; p=0.18) or MACE (RR: 1.16; 95% CI: 0.90--1.50; p=0.30). In patients undergoing non-cardiac surgery, preoperative use of clopidogrel increased the RR of re-operation for major bleeding by 2.05-fold (95% CI: 1.13-3.73; p=0.002) but did not reduce the RR for MACE or death. Clopidogrel use during cardiac device implantation raised the RR for procedure-related haematoma by 3.0-fold (95% CI: 1.30--6.94; p=0.001). Whereas preoperative ticagrelor use did not increase the risk for mortality (RR: 1.03; 95% CI: 0.49-2.14), preoperative prasugrel use tended to increase the risk for death (RR: 5.06; 95% CI: 0.54-47.65). CONCLUSION: Preoperative exposure to clopidogrel on top of aspirin did not reduce the risk of MACE but was associated with increased risk of bleeding and mortality. [less ▲]

Detailed reference viewed: 20 (1 ULg)
Full Text
Peer Reviewed
See detailBilateral internal thoracic artery grafts for myocardial revascularization in insulin-dependent diabetic patients: time for wide clinical practice?
Jatene, Fabio Biscegli; Kolh, Philippe ULg

in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2015), 48(1), 121-2

Detailed reference viewed: 15 (0 ULg)
Full Text
Peer Reviewed
See detailSurgical or percutaneous revascularization for isolated left anterior descending stenoses: are we in the same boat?
Stefanini, Giulio; Windecker, Stephan; Kolh, Philippe ULg

in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2015)

Detailed reference viewed: 11 (3 ULg)
Full Text
Peer Reviewed
See detail2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).
Elliott, Perry M.; Anastasakis, Aris; Borger, Michael A. et al

in European heart journal (2014), 35(39), 2733-79

Detailed reference viewed: 37 (0 ULg)
Full Text
Peer Reviewed
See detailRevascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis.
Windecker, Stephan; Stortecky, Stefan; Stefanini, Giulio G. et al

in BMJ (Clinical research ed.) (2014), 348

OBJECTIVE: To investigate whether revascularisation improves prognosis compared with medical treatment among patients with stable coronary artery disease. DESIGN: Bayesian network meta-analyses to combine ... [more ▼]

OBJECTIVE: To investigate whether revascularisation improves prognosis compared with medical treatment among patients with stable coronary artery disease. DESIGN: Bayesian network meta-analyses to combine direct within trial comparisons between treatments with indirect evidence from other trials while maintaining randomisation. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: A strategy of initial medical treatment compared with revascularisation by coronary artery bypass grafting or Food and Drug Administration approved techniques for percutaneous revascularization: balloon angioplasty, bare metal stent, early generation paclitaxel eluting stent, sirolimus eluting stent, and zotarolimus eluting (Endeavor) stent, and new generation everolimus eluting stent, and zotarolimus eluting (Resolute) stent among patients with stable coronary artery disease. DATA SOURCES: Medline and Embase from 1980 to 2013 for randomised trials comparing medical treatment with revascularisation. MAIN OUTCOME MEASURE: All cause mortality. RESULTS: 100 trials in 93,553 patients with 262,090 patient years of follow-up were included. Coronary artery bypass grafting was associated with a survival benefit (rate ratio 0.80, 95% credibility interval 0.70 to 0.91) compared with medical treatment. New generation drug eluting stents (everolimus: 0.75, 0.59 to 0.96; zotarolimus (Resolute): 0.65, 0.42 to 1.00) but not balloon angioplasty (0.85, 0.68 to 1.04), bare metal stents (0.92, 0.79 to 1.05), or early generation drug eluting stents (paclitaxel: 0.92, 0.75 to 1.12; sirolimus: 0.91, 0.75 to 1.10; zotarolimus (Endeavor): 0.88, 0.69 to 1.10) were associated with improved survival compared with medical treatment. Coronary artery bypass grafting reduced the risk of myocardial infarction compared with medical treatment (0.79, 0.63 to 0.99), and everolimus eluting stents showed a trend towards a reduced risk of myocardial infarction (0.75, 0.55 to 1.01). The risk of subsequent revascularisation was noticeably reduced by coronary artery bypass grafting (0.16, 0.13 to 0.20) followed by new generation drug eluting stents (zotarolimus (Resolute): 0.26, 0.17 to 0.40; everolimus: 0.27, 0.21 to 0.35), early generation drug eluting stents (zotarolimus (Endeavor): 0.37, 0.28 to 0.50; sirolimus: 0.29, 0.24 to 0.36; paclitaxel: 0.44, 0.35 to 0.54), and bare metal stents (0.69, 0.59 to 0.81) compared with medical treatment. CONCLUSION: Among patients with stable coronary artery disease, coronary artery bypass grafting reduces the risk of death, myocardial infarction, and subsequent revascularisation compared with medical treatment. All stent based coronary revascularisation technologies reduce the need for revascularisation to a variable degree. Our results provide evidence for improved survival with new generation drug eluting stents but no other percutaneous revascularisation technology compared with medical treatment. [less ▲]

Detailed reference viewed: 34 (0 ULg)
Full Text
Peer Reviewed
See detailNetworks for improving care in patients with acute coronary syndrome: A framework.
Radke, Peter W.; Halvorsen, Sigrun; Jukema, J. Wouter et al

in Acute cardiac care (2014), 16(2), 41-8

In recent years, it has become evident that the level of guideline adherence in patients presenting with acute coronary syndrome (ACS) is highly correlated with patient outcomes. Unfortunately, guideline ... [more ▼]

In recent years, it has become evident that the level of guideline adherence in patients presenting with acute coronary syndrome (ACS) is highly correlated with patient outcomes. Unfortunately, guideline adherence is low in some geographic areas and especially in those patients at high-risk. Regional networks including ambulance systems and hospitals with catheterization laboratories are able to increase guideline adherence and patient outcomes by streamlining the critical pre- and intra-hospital processes as well as improving timely access to invasive procedures and recommended medication. Successful organization of an ACS network requires engagement of multiple stakeholders to create effective solutions for the specific local setting. There is no 'one-size-fits all' strategy to set-up and successfully run an ACS network. We present a framework for how to set up and organize an effective ACS network, delivering guideline-based care to improve patient outcomes. [less ▲]

Detailed reference viewed: 22 (4 ULg)
Full Text
See detailRevascularisation en cas d’artériopathie périphérique du membre inférieur – Résumé.
Vlayen, Joan; Holdt Henningsen, Kirsten; d’Archambeau, Olivier, Olivier et al

Report (2014)

Detailed reference viewed: 48 (6 ULg)
Full Text
Peer Reviewed
See detailESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary.
Ryden, Lars; Grant, Peter J.; Anker, Stefan D. et al

in Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease (2014), 11(3), 133-73

Detailed reference viewed: 25 (1 ULg)
Full Text
Peer Reviewed
See detail2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.
Brignole, Michele; Auricchio, Angelo; Baron-Esquivias, Gonzalo et al

in Revista espanola de cardiologia (English ed.) (2014), 67(1), 58

Detailed reference viewed: 14 (0 ULg)
Full Text
Peer Reviewed
See detailRemote ischaemic pre-conditioning in cardiac surgery: benefit or not?
Kolh, Philippe ULg

in European heart journal (2014), 35(3), 141-3

Detailed reference viewed: 10 (0 ULg)
Full Text
Peer Reviewed
See detailDe l’enregistrement des données infirmières à la mise en évidence de profils de soins.
THONON, Olivier ULg; LAPORT, Nancy; GILLAIN, Daniel et al

in Actes de la 6ème conférence francophone en Gestion et Ingénierie des SystèmEs Hospitaliers - GISEH (2014)

Detailed reference viewed: 37 (3 ULg)